FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with omeprazole 20 mg once a day had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir).
Estonian: Omeprasoolravil annuses 20 mg üks kord ööpäevas ei ilmnenud toimet darunaviiri ega amprenaviiri ekspositsioonidele (mõlemad ravimid kombinatsioonis ritonaviiriga).
English: • Phenytoin (used to treat epilepsy)
Estonian: • fenütoiin (kasutatakse epilepsia raviks);
English: In a study in healthy subjects, there was a decreased exposure by almost 40% of the active metabolite of clopidogrel when a fixed dose combination of esomeprazole 20 mg + acetylsalicylic acid 81 mg was given with clopidogrel compared to clopidogrel alone.
Estonian: Tervetel vabatahtlikel läbiviidud uuringus, milles manustati klopidogreeli koos fikseeritud annuses esomeprasooli (20 mg) ja atsetüülsalitsüülhappega (81 mg) võrreldes ainult klopidogreeli saava rühmaga, langes klopidogreeli aktiivse metaboliidi plasmakontsentratsioon peaaegu 40%.
English: Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5).
Estonian: Esomeprasooli ja atasanaviiri samaaegne manustamine ei ole soovitatav (vt lõik 4.5).
English: Omeprazole as well as esomeprazole act as inhibitors of CYP2C19.
Estonian: Omeprasool ja esomeprasool omavad CYP2C19 pärssivat toimet.
English: Nexium Control 20 mg Capsules
Estonian: Nexium Control 20 mg kapslid
English: General disorders and administration site disorders malaise, increased sweating
Estonian: Üldised häired ja manustamiskoha reaktsioonid halb enesetunne, liighigistamine
English: However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in both groups.
Estonian: Siiski, (ADP indutseeritud) trombotsüütide agregatsiooni maksimaalse pärssimise tase oli võrdne klopidogreeli ja klopidogreel+kombinatsiooni (esomeprasool ja atsetüülsalitsüülhape) rühmades.
English: Reddish-brown iron oxide (E172)
Estonian: Punakaspruun raudoksiid (E172)
English: Esomeprazole is a CYP2C19 inhibitor.
Estonian: Esomeprasool omab CYP2C19 pärssivat toimet.
English: • Swallow your capsule whole with half a glass of water.
Estonian: Neelake kapsel tervena koos poole klaasitäie veega.
English: Eye disorders blurred vision
Estonian: Silma kahjustused hägune nägemine
English: • Swallow your tablet whole with half a glass of water.
Estonian: Neelake tablett tervena koos poole klaasitäie veega.
English: Capsule shell Gelatin
Estonian: Propüleenglükool Šellak
English: )), resulted in a doubling of the exposure (AUC) to esomeprazole.
Estonian: Raske maksa funktsiooni häirega patsientidel on esomeprasooli AUC kahekordistunud.
English: Reproductive system and breast disorders gynaecomastia
Estonian: Reproduktiivse süsteemi ja rinnanäärme häired günekomastia
English: • Cisapride (used for indigestion and heartburn)
Estonian: • tsisapriid (kasutatakse seedehäirete ja kõrvetiste raviks);
English: Nexium Control 20 mg gastro-resistant tablets esomeprazole
Estonian: Nexium Control 20 mg gastroresistentsed tabletid esomeprasool
English: Cisapride
Estonian: Kapslid
English: Each gastro-resistant capsule contains 20 mg esomeprazole (as magnesium trihydrate).
Estonian: Üks gastroresistentne kapsel sisaldab 20 mg esomeprasooli (magneesiumtrihüdraadina).
English: Nexium Control 20 mg gastro-resistant tablets
Estonian: Nexium Control, 20 mg gastroresistentsed tabletid
English: Blood and lymphatic system disorders leukopenia, thrombocytopenia agranulocytosis, pancytopenia
Estonian: Vere ja lümfisüsteemi häired leukopeenia, trombotsütopeenia agranulotsütoos, pantsütopeenia
English: Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium trihydrate).
Estonian: Üks gastroresistentne tablett sisaldab 20 mg esomeprasooli (magneesiumtrihüdraadina).
English: Sucrose
Estonian: Tsisapriid
English: For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended.
Estonian: Omeprasooliga koosmanustamisel on teatatud atasanaviiri ja nelfinaviiri sisalduse vähenemisest seerumis, mistõttu koosmanustamine ei ole soovitav.
English: Österreich, Eesti, Hrvatska, Latvija, Lietuva, Slovenija, България Pfizer Corporation Austria GmbH (Austria/Austrija/Avstrija/Австрия) Consumer Healthcare Tel.: +43 (0)1 521 15-0
Estonian: Pfizer Corporation Austria GmbH (Austria/Austrija/Avstrija/Австрия) Consumer Healthcare
English: The use of esomeprazole with clopidogrel should be discouraged (see section 4.5).
Estonian: subakuutne naha erütematoosn e luupus (vt lõik 4.4)
English: The area under the plasma concentration-time curve increases with repeated administration of esomeprazole.
Estonian: On teatatud takroliimuse plasmakontsentratsiooni tõusust esomeprasooli samaaegsel manustamisel.
English: • Blood problems such as a reduced number of white blood cells or platelets.
Estonian: Harva esinevad (esinevad kuni ühel kasutajal 1000st) muutused veres, nagu vähenenud valgeliblede või vereliistakute arv.
English: Nexium Control 20 mg gastro-resistant capsules esomeprazole
Estonian: Nexium Control 20 mg gastroresistentsed kapslid esomeprasool
English: • Sudden wheezing, swelling of your lips, tongue and throat, rash, fainting, or difficulties in swallowing (severe allergic reaction, seen rarely).
Estonian: Lõpetage Nexium Controli võtmine ja pöörduge viivitamatult oma arsti poole, kui märkate ükskõik millist järgmistest tõsistest kõrvaltoimetest: äkki tekkinud vilistav hingamine, huulte, keele ja kurgu turse, nahalööve, minestamine või neelamisraskused (raske allergiline reaktsioon, tekib harva); nahapunetus koos villide tekkega või naha koorumisega.
English: Band
Estonian: Riba
English: Ear and labyrinth disorders vertigo
Estonian: Kõrva ja labürindi kahjustused vertiigo
English: It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.
Estonian: Kui ravi esomeprasooliga on alustatud või lõpetatud, on soovitav jälgida fenütoiini kontsentratsiooni plasmas.
English: What you need to know before you take Nexium Control 3.
Estonian: Mis ravim on Nexium Control ja milleks seda kasutatakse Mida on vaja teada enne Nexium Controli kasutamist Kuidas Nexium Controli kasutada Võimalikud kõrvaltoimed
English: When given together with PPIs, methotrexate levels have been reported to increase in some patients.
Estonian: Mõnedel juhtudel on teatatud metotreksaadi taseme tõusust, kui metotreksaati on kasutatud samaaegselt prootonpumba inhibiitoritega.
English: lansoprazole, rabeprazole or omeprazole).
Estonian: nahalööve, nõgeslöve, nahasügelus.
English: • Effects on your stomach or gut: diarrhoea, stomach ache, constipation, wind (flatulence).
Estonian: Sageli esinevad (esinevad kuni ühel kasutajal 10st) peavalu; toimed mao või soolestiku poolt: kõhulahtisus, kõhuvalu, kõhukinnisus, kõhupuhitus (gaasid); iiveldus või oksendamine; healoomulised maopolüübid.
English: MiPet Easecto sarolaner
Estonian: MiPet Easecto sarolaneer
English: The full EPAR for MiPet Easecto can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst MiPet Easecto kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: This medicine is the same as Simparica, which is already authorised in the EU.
Estonian: See ravim on samane Simparicaga, millel juba on Euroopa Liidus müügiluba.
English: This summary was last updated in October 2017.
Estonian: Kokkuvõtte viimane uuendus: 10-2017.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that MiPet Easecto's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et MiPet Easecto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: This authorisation was based on the authorisation granted to Simparica in 2015 (‘informed consent').
Estonian: Müügiluba põhineb 2015. aastal antud Simparica müügiloal (teabel põhinev nõusolek).
English: What is MiPet Easecto and what is it used for?
Estonian: Mis on MiPet Easecto ja milleks seda kasutatakse?
English: MiPet Easecto was as effective as moxidectin/imidacloprid and the percentage of MiPet Easecto-treated dogs with no live mites was 15%, 69%, 93%, 94%, 100% and 100% on days 30, 60, 90, 120, 150 and 180, respectively.
Estonian: MiPet Easecto oli sama efektiivne kui moksidektiin/imidaklopriid: eluslestadeta koeri oli MiPet Easecto ravirühmas 30., 60., 90., 120., 150. ja 180. päeval vastavalt 15%, 69%, 93%, 94%, 100% ja 100%.
English: The company that makes Simparica has agreed that its scientific data can be used for MiPet Easecto (‘informed consent').
Estonian: Simparica tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka MiPet Easecto toetuseks (teabel põhinev nõusolek).
English: MiPet Easecto is available as chewable tablets (5, 10, 20, 40, 80 and 120 mg) and can only be obtained with a prescription.
Estonian: MiPet Easectot turustatakse närimistablettidena (5, 10, 20, 40, 80 ja 120 mg).
English: However, the following side effects are seen in less than 1 dog in 10,000: mild and short-lived vomiting and diarrhoea as well as tremor (shaking), ataxia (inability to coordinate body movements) or convulsions.
Estonian: Vähem kui 1 koeral 10 000st on siiski esinenud järgmised kõrvaltoimed: kerge lühiajaline oksendamine ja kõhulahtisus, samuti treemor (värin), ataksia (liigutuste koordinatsioonihäired) või konvulsioonid.
English: The appropriate strength tablet should be used according to the dog's weight.
Estonian: Kasutada tuleb koera kaalule vastava tugevusega tabletti.
English: MiPet Easecto is a veterinary medicine used to treat infestations with ticks and fleas, demodectic and sarcoptic mange (skin infestations caused by two different types of mites) and ear mite infestations in dogs.
Estonian: MiPet Easecto on veterinaarravim, mida kasutatakse puugi- ja kirbunakkuste, demodektoosi ja sarkoptoosi (kahe eri lesta põhjustatud nahanakkused) ja kõrvasügelislestanakkuste raviks koertel.
English: Why is MiPet Easecto approved?
Estonian: Miks MiPet Easecto heaks kiideti?
English: Other information about MiPet Easecto
Estonian: Muu teave ravimi MiPet Easecto kohta
English: This is a summary of the European public assessment report (EPAR) for MiPet Easecto.
Estonian: See on ravimi MiPet Easecto Euroopa avaliku hindamisaruande kokkuvõte.
English: It is not intended to provide practical advice on how to use MiPet Easecto.
Estonian: Hindamisaruandes ei anta MiPet Easecto kasutamise praktilisi nõuandeid.
English: What are the risks associated with MiPet Easecto?
Estonian: Mis riskid MiPet Easectoga kaasnevad?
English: MiPet Easecto can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Estonian: MiPet Easectot tohib kasutada kirbuallergiast põhjustatud dermatiidi (allergiline reaktsioon kirbuhammustustele) ravi osana.
English: For treatment of tick and flea infestations MiPet Easecto should be given once every month throughout the flea and/or tick season for optimal control.
Estonian: Puugi- ja kirbunakkuste optimaalseks tõrjeks tuleb MiPet Easectot anda kord kuus kogu kirbu- ja/või puugihooaja vältel.
English: MiPet Easecto was as effective as moxidectin/imidacloprid.
Estonian: MiPet Easecto oli sama efektiivne kui moksidektiin/imidaklopriid.
English: For practical information about using MiPet Easecto, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad MiPet Easecto kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: Safety information has been included in the summary of product characteristics and the package leaflet for MiPet Easecto, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Estonian: Ravimi omaduste kokkuvõttesse ja pakendi infolehele lisati MiPet Easecto ohutusteave, kus on ka tervishoiuspetsialistide ja loomaomanike või -pidajate võetavad meetmed.
English: For MiPet Easecto the percentage of dogs with no live ear mites present was 91% at day 30 increasing to 99% on day 60, following two treatments.
Estonian: MiPet Easectoga tehtud ravi 30. päeval puudusid elusad kõrvasügelislestad 91%-l koertest ja 60. päeval, kahe ravikuuri järel, 99%-l koertest.
English: For treatment of demodectic mange MiPet Easecto should be given once a month for at least three months.
Estonian: Demodektoosi raviks tuleb MiPet Easectot manustada kord kuus vähemalt kolm kuud.
English: After MiPet Easecto is given its activity against ticks and fleas lasts for at least 5 weeks.
Estonian: Pärast MiPet Easecto manustamist püsib puugi- ja kirbuvastane toime vähemalt 5 nädalat.
English: In a study involving dogs with ear mite infestation, 283 dogs were treated with MiPet Easecto and 131 dogs received moxidectin/imidacloprid (a spot-on mite treatment).
Estonian: Kõrvasügelislestanakkusega koerte uuringus raviti 283 koera MiPet Easectoga ja 131 koera moksidektiini/imidaklopriidiga (lestaraviks kasutatav täpilahus).
English: In a study with 98 dogs with demodectic mange, 63 dogs were treated with MiPet Easecto monthly for up to six months and 35 dogs received moxidectin/imidacloprid.
Estonian: Demodektoosi uuringus (98 koera) raviti 63 koera iga kuu kuni 6 kuud MiPet Easectoga ja 35 koera moksidektiini/imidaklopriidiga.
English: How does MiPet Easecto work?
Estonian: Kuidas MiPet Easecto toimib?
English: The effectiveness of MiPet Easecto against fleas was investigated in a field study in dogs infested with at least five live fleas.
Estonian: Ühes väliuuringus uuriti MiPet Easecto kirpudevastast tõhusust koertel, kellel esines vähemalt viis elus kirpu.
English: 189 dogs were treated with MiPet Easecto for three months whilst 96 dogs were given another medicine, spinosad.
Estonian: Kolme kuu jooksul raviti 189 koera MiPet Easectoga ja 96 koera spinosaadiga (teine ravim).
English: The European Commission granted a marketing authorisation valid throughout the EU for MiPet Easecto on 31 January 2018.
Estonian: Euroopa Komisjon andis MiPet Easectole müügiloa, mis kehtib kogu Euroopa Liidu territooriumil,
English: For treatment of sarcoptic mange, MiPet Easecto is given monthly for two consecutive months.
Estonian: Sarkoptoosi raviks tuleb MiPet Easectot manustada kord kuus kahel järjestikusel kuul.
English: 53 dogs were treated with MiPet Easecto for two months whilst 26 dogs were given a medicine containing moxidectin and imidacloprid.
Estonian: Kahe kuu jooksul raviti 53 koera MiPet Easectoga ning 26 koera moksidektiini ja imidaklopriidi sisaldava ravimiga.
English: MiPet Easecto was as effective as spinosad in reducing flea counts for up to 90 days after treatment.
Estonian: MiPet Easecto oli kirpude arvu vähendamisel kuni 90 päeva pärast ravi sama efektiivne kui spinosaad.
English: What benefits of MiPet Easecto have been shown in studies?
Estonian: Milles seisneb uuringute põhjal MiPet Easecto kasulikkus?
English: MiPet Easecto was as effective as fipronil in reducing tick counts for up to 90 days after treatment.
Estonian: MiPet Easecto oli puukide arvu vähendamisel kuni 90 päeva pärast ravi sama efektiivne kui fiproniil.
English: 122 dogs were treated with MiPet Easecto for three months whilst 59 dogs were treated with another medicine, fipronil, against ticks.
Estonian: Kolme kuu jooksul raviti 122 koera MiPet Easectoga ja 59 koera fiproniiliga (teine puugiravim).
English: How is MiPet Easecto used?
Estonian: Kuidas MiPet Easectot kasutatakse?
English: MiPet Easecto was as effective as moxidectin and imidacloprid in eliminating live mites in skin scrapings.
Estonian: Nahakaabete põhjal oli MiPet Easecto eluslestade hävitamisel sama efektiivne kui moksidektiin ja imidaklopriid.
English: This means that it kills parasites that live on the skin or in the fur of animals, such as fleas, ticks and mites.
Estonian: MiPet Easecto toimeaine sarolaneer toimib ektoparasititsiidina: see hävitab loomade nahal või karvades elavaid parasiite, nagu kirbud, puugid ja lestad.
English: • Risk management plan (RMP) Not applicable.
Estonian: • Riskijuhtimiskava Ei kohaldata.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/11/741/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/11/741/001
English: INFORMATION IN BRAILLE Justification for not including Braille accepted
Estonian: Põhjendus Braille' mitte lisamiseks heaks kiidetud
English: Date of latest renewal: 14 November 2016
Estonian: Müügiloa viimase uuendamise kuupäev: 14. november 2016
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 December 2011
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 14. detsember 2011
English: No clinical data are available, potential risk for human is unknown.
Estonian: Kliinilisedi andmed puuduvad, võimalik risk inimesele on teadmata.
English: Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.
Estonian: Informatsioon olemasolevate andmete kohta on lõigus 4.8, 5.1 ja 5.2, kuid annustamissoovitused puuduvad.
English: Polska Ranbaxy (Poland) Sp. Z o. o.
Estonian: Ranbaxy (Poland) Sp. Z o. o. ul.
English: EXP Use immediately after dilution.
Estonian: EXP Kasutada koheselt pärast lahustamist.
English: Levetiracetam SUN must be administered twice a day, once in the morning and once in the evening, at about the same time each day.
Estonian: Ravimit Levetiracetam SUN tuleb manustada kaks korda ööpäevas, üks kord hommikul ja üks kord õhtul, iga päev enam-vähem samal ajal.
English: Infusion Time
Estonian: Infusiooni aeg
English: NL-2132 JH Hoofddorp The Netherlands
Estonian: NL-2132 JH Hoofddorp Holland
English: The mechanism of this risk is not known.
Estonian: Selle mehhanism pole teada.
English: Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase.
Estonian: Võimaliku erineva individuaalse tundlikkuse tõttu võivad mõnel patsiendil tekkida unisus või teisedi kesknärvisüsteemiga seotud sümptomid, eriti ravi alguses või pärast annuse suurendamist.
English: This leaflet was last revised in {month/YYYY} Other sources of information
Estonian: Infoleht on viimati uuendatud {kuu AAAA} Muud teabeallikad
English: In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines.
Estonian: Lisaks sellele pöörab ta ka osaliselt tagasi tsingi ja β-karboliinide poolt põhjustatud GABA- ja glütsiinitundlike voolude vähenemise.
English: The following information is intended for healthcare professionals only: Directions for the proper use of Levetiracetam SUN is provided in section 3.
Estonian: Järgnev teave on ainult tervishoiutöötajatele: Juhised Levetiracetam SUN-i õigeks manustmiseks on antud lõigus 3.
English: If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Estonian: Kui seda otsekohe ei kasutata, vastutab ravimi säilitamise aja ja tingimuste eest kasutaja ning see ei tohiks tavaliselt olla enam kui 24 tundi hoituna temperatuuril 2 °C…8 °C, juhul kui lahjendatud lahus on hoitud kontrollitud ja valideeritud aseptilistes tingimustes.
English: Your total daily dose and frequency of administration remain the same.
Estonian: Teie ööpäevane koguannus ja manustamissagedus jäävad samaks.
English: Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardized and systematic way using a validated instrument (CBCL - Achenbach Child Behavior Checklist).
Estonian: Käitumuslike ja emotsionaalsete funktsioonidega seotud tulemused näitasid levetiratsetaamravi saanud patsientide agressiivse käitumise halvenemist, mida mõõdetakse standardiseeritult ja süstematiseeritult, kasutades valideeritud meetodit (CBCL - Achenbach Child Behavior Checklist).
English: Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: -7.8 8.2).
Estonian: Kuuekuune krambivaba periood saavutati 73,0% levetiratsetaamiga ravitud patsientidest ning 72,8% karbamasepiin CR-iga ravitud patsientidest; kohandatud absoluutne erinevus ravigruppide vahel oli 0,2% (95% CI: -7,8 8,2).
English: Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥ 1/100 to <1/10); uncommon: (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000) and very rare (<1/10,000).
Estonian: Kõrvaltoimed on esitatud tõsiduse vähenemise järjekorras ja nende esinemissagedust defineeritakse järgmiselt: väga sage (≥1/10); sage (≥1/100 kuni <1/10); aeg-ajalt (≥1/1000 kuni <1/100); harv (≥1/10 000 kuni <1/1000) ja väga harv.
English: The pharmacokinetics in paediatric patients has not been investigated after intravenous administration.
Estonian: Pediaatrilistel patsientidel farmakokineetikat intravenoosse manustamise järgselt ei ole uuritud.
English: If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Estonian: Rasedus ja imetamine Kui te olete rase, imetate või arvate end olevat rase või kavatsete rasestuda, pidage enne selle ravimi kasutamist nõu oma arstiga.
English: Levetiracetam SUN may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Estonian: Levetiracetam SUN võib mõjutada teie võimet juhtida autot või käsitseda masinaid, sest see ravim võib muuta teid uniseks.
English: What Levetiracetam SUN is and what is it used for
Estonian: Mis ravim on Levetiracetam SUN ja milleks seda kasutatakse
English: For storage conditions of the diluted medicinal product, see section 6.3.
Estonian: Lahjendatud ravimlahuse säilitamise tingimusi vt lõik 6.3.
English: Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you.
Estonian: Enne selle ravimi kasutamist endal või oma lapsel, lugege hoolikalt infolehte, sest siin on teile vajalikku teavet.
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Estonian: Teatage oma arstile või apteekrile, kui te kasutate, olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid.
English: The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.
Estonian: Kehakaalu järgi kohandatud kliirens oli ligikaudu 30% suurem kui epilepsiaga täiskasvanutel.
English: However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.
Estonian: Kui levetiratsetaamravi on vajalik rinnaga toitmise ajal, siis tuleb hinnata ravi kasu/riski suhet.
English: Other medicines and Levetiracetam SUN
Estonian: Muud ravimid ja Levetiracetam SUN
English: To be taken into consideration by patients on a controlled sodium diet.
Estonian: Sellega peavad arvestama kontrollitud soolasisaldusega dieeti vajavad patsiendid.
English: In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores.
Estonian: In vitro uuringud näitavad , et levetiratsetaam mõjutab intraneuronaalset Ca2+ ioonide sisaldust pärssides osaliselt N-tüüpi Ca-kanaleid ja vähendades Ca2+ vabanemist rakusisestest depoodest.